sky hero image

In the APOLLO study, treatment with ONPATTRO® (patisiran) led to a rapid and powerful reduction in serum TTR1

  • Serum TTR was evaluated in patients with hATTR amyloidosis with polyneuropathy treated with 0.3 mg/kg ONPATTRO via intravenous infusion once every 3 weeks1

    Mean serum TTR was reduced by approximately 80% within 10 to 14 days after a single dose1

    The mean maximum serum TTR reduction was 88% from baseline over 18 months1

    Reduction was observed regardless of TTR mutation, sex, age, or race1

    In an ongoing open-label extension (OLE) study, TTR reduction was maintained up to 4 years with continued dosing3

84% mean reduction of
serum TTR
at 18 months1,2,a

Mean serum TTR reduction with ONPATTRO® (patisiran)

aBars represent SEM (standard error of the mean).

Adapted from New England Journal of Medicine, Adams D, Gonzalez-Duarte A, O’Riordan WD, et al, “Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis,” 379(1). Copyright © 2018 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.



  1. ONPATTRO [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc; 2018.
  2. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. N Engl J Med. 2018;379(1):11-21.
  3. Gonzalez-Duarte A, Coelho T, Adams D, et al. Poster presented at AANEM Annual Meeting; October 10-13, 2018; Washington, DC.